Risperidone in the treatment of dopamine‐induced psychosis in Parkinson's disease: An open pilot trial
Identifieur interne : 004969 ( Main/Exploration ); précédent : 004968; suivant : 004970Risperidone in the treatment of dopamine‐induced psychosis in Parkinson's disease: An open pilot trial
Auteurs : Erich Mohr [Canada] ; Tilak Mendis [Canada] ; Kathleen Hildebrand [Canada] ; Peter Paul De Deyn [Belgique]Source :
- Movement Disorders [ 0885-3185 ] ; 2000-11.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antiparkinson Agents (adverse effects), Antiparkinson agent, Antipsychotic Agents (therapeutic use), Belgium, Canada, Chemotherapy, Dopamine (adverse effects), Dopamine Antagonists (therapeutic use), Dopamine antagonist, Dopamine receptor, Dose-Response Relationship, Drug, Drug Therapy, Combination, Extrapyramidal symptoms, Female, Human, Humans, Levodopa, Male, Middle Aged, Neuroleptic, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Pilot Projects, Psychiatric Status Rating Scales, Psychoses, Substance-Induced (drug therapy), Psychosis, Psychotropic, Risperidone, Risperidone (therapeutic use), Serotonin antagonist, Serotonine receptor, Short term, Toxicity, Treatment, Treatment Outcome.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Dopamine.
- chemical , therapeutic use : Antipsychotic Agents, Dopamine Antagonists, Risperidone.
- geographic : Belgium, Canada.
- complications : Parkinson Disease.
- drug therapy : Parkinson Disease, Psychoses, Substance-Induced.
- Adult, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Pilot Projects, Psychiatric Status Rating Scales, Treatment Outcome.
Abstract
PURPOSE: To evaluate the safety and efficacy of risperidone in patients with Parkinson's disease (PD) who are experiencing significant dopamine‐induced psychosis. PATIENTS AND METHODS: Seventeen patients (median age, 72 yrs) participated in this 12‐week, open pilot study receiving 0.5 to 3 mg oral risperidone per day. Maintenance antiparkinsonian medication was continued throughout, although psychotropic medication was discontinued. EFFICACY RESULTS: Risperidone produced a substantial improvement in psychotic symptoms, shown on the mean total positive subscale score on the Positive and Negative Syndrome Scale (PANSS) by a 30% improvement (−3.1 decrease) after 1 week and a 66% improvement (−6.8 decrease) at end point. This improvement was most evident in the items delusions, hallucinatory behavior, and suspiciousness/persecution. Risperidone also achieved significant improvement from baseline in Clinical Global Impression (CGI)‐severity and CGI‐improvement (p <0.001, Page test). Risperidone treatment did not adversely affect symptoms specific to Parkinson's disease, as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS). SAFETY RESULTS: Sixteen patients reported at least one adverse event, but only two patients withdrew as a result of adverse events. No significant changes or clinically relevant abnormalities were observed in laboratory parameters or vital signs. CONCLUSION: Short‐term use of risperidone (mean dosage, 1.1 mg per day) improves the psychopathology of patients with PD who have dopamine‐induced psychosis without adversely affecting the symptoms of PD. Higher doses and long‐term use were not addressed in this study and may be precluded by extrapyramidal side effects.
Url:
DOI: 10.1002/1531-8257(200011)15:6<1230::AID-MDS1026>3.0.CO;2-9
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000900
- to stream Istex, to step Curation: 000900
- to stream Istex, to step Checkpoint: 003169
- to stream Main, to step Merge: 007266
- to stream PascalFrancis, to step Corpus: 002A81
- to stream PascalFrancis, to step Curation: 000240
- to stream PascalFrancis, to step Checkpoint: 002B23
- to stream Main, to step Merge: 007515
- to stream PubMed, to step Corpus: 003E54
- to stream PubMed, to step Curation: 003E54
- to stream PubMed, to step Checkpoint: 003E83
- to stream Ncbi, to step Merge: 000397
- to stream Ncbi, to step Curation: 000397
- to stream Ncbi, to step Checkpoint: 000397
- to stream Main, to step Merge: 007026
- to stream Main, to step Curation: 004969
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Risperidone in the treatment of dopamine‐induced psychosis in Parkinson's disease: An open pilot trial</title><author><name sortKey="Mohr, Erich" sort="Mohr, Erich" uniqKey="Mohr E" first="Erich" last="Mohr">Erich Mohr</name></author><author><name sortKey="Mendis, Tilak" sort="Mendis, Tilak" uniqKey="Mendis T" first="Tilak" last="Mendis">Tilak Mendis</name></author><author><name sortKey="Hildebrand, Kathleen" sort="Hildebrand, Kathleen" uniqKey="Hildebrand K" first="Kathleen" last="Hildebrand">Kathleen Hildebrand</name></author><author><name sortKey="De Deyn, Peter Paul" sort="De Deyn, Peter Paul" uniqKey="De Deyn P" first="Peter Paul" last="De Deyn">Peter Paul De Deyn</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8B1FBAD976A77EB092B13F06364277175FC64B7A</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1002/1531-8257(200011)15:6<1230::AID-MDS1026>3.0.CO;2-9</idno><idno type="url">https://api.istex.fr/document/8B1FBAD976A77EB092B13F06364277175FC64B7A/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000900</idno><idno type="wicri:Area/Istex/Curation">000900</idno><idno type="wicri:Area/Istex/Checkpoint">003169</idno><idno type="wicri:doubleKey">0885-3185:2000:Mohr E:risperidone:in:the</idno><idno type="wicri:Area/Main/Merge">007266</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:01-0017681</idno><idno type="wicri:Area/PascalFrancis/Corpus">002A81</idno><idno type="wicri:Area/PascalFrancis/Curation">000240</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002B23</idno><idno type="wicri:doubleKey">0885-3185:2000:Mohr E:risperidone:in:the</idno><idno type="wicri:Area/Main/Merge">007515</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:11104211</idno><idno type="wicri:Area/PubMed/Corpus">003E54</idno><idno type="wicri:Area/PubMed/Curation">003E54</idno><idno type="wicri:Area/PubMed/Checkpoint">003E83</idno><idno type="wicri:Area/Ncbi/Merge">000397</idno><idno type="wicri:Area/Ncbi/Curation">000397</idno><idno type="wicri:Area/Ncbi/Checkpoint">000397</idno><idno type="wicri:doubleKey">0885-3185:2000:Mohr E:risperidone:in:the</idno><idno type="wicri:Area/Main/Merge">007026</idno><idno type="wicri:Area/Main/Curation">004969</idno><idno type="wicri:Area/Main/Exploration">004969</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Risperidone in the treatment of dopamine‐induced psychosis in Parkinson's disease: An open pilot trial</title><author><name sortKey="Mohr, Erich" sort="Mohr, Erich" uniqKey="Mohr E" first="Erich" last="Mohr">Erich Mohr</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>CroMedica Global Inc., Victoria, Canada and University of Ottawa</wicri:regionArea><wicri:noRegion>Canada and University of Ottawa</wicri:noRegion></affiliation></author><author><name sortKey="Mendis, Tilak" sort="Mendis, Tilak" uniqKey="Mendis T" first="Tilak" last="Mendis">Tilak Mendis</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Ottawa Civic Hospital and University of Ottawa</wicri:regionArea></affiliation></author><author><name sortKey="Hildebrand, Kathleen" sort="Hildebrand, Kathleen" uniqKey="Hildebrand K" first="Kathleen" last="Hildebrand">Kathleen Hildebrand</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>CroMedica Global Inc., Victoria, Canada and University of Ottawa</wicri:regionArea><wicri:noRegion>Canada and University of Ottawa</wicri:noRegion></affiliation></author><author><name sortKey="De Deyn, Peter Paul" sort="De Deyn, Peter Paul" uniqKey="De Deyn P" first="Peter Paul" last="De Deyn">Peter Paul De Deyn</name><affiliation wicri:level="4"><country xml:lang="fr">Belgique</country><wicri:regionArea>Middelheim Hospital, University of Antwerp, Antwerp</wicri:regionArea><orgName type="university">Université d'Anvers</orgName><placeName><settlement type="city">Anvers</settlement><region type="district" nuts="2">Province d'Anvers</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2000-11">2000-11</date><biblScope unit="vol">15</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="1230">1230</biblScope><biblScope unit="page" to="1237">1237</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">8B1FBAD976A77EB092B13F06364277175FC64B7A</idno><idno type="DOI">10.1002/1531-8257(200011)15:6<1230::AID-MDS1026>3.0.CO;2-9</idno><idno type="ArticleID">MDS1026</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson agent</term><term>Antipsychotic Agents (therapeutic use)</term><term>Belgium</term><term>Canada</term><term>Chemotherapy</term><term>Dopamine (adverse effects)</term><term>Dopamine Antagonists (therapeutic use)</term><term>Dopamine antagonist</term><term>Dopamine receptor</term><term>Dose-Response Relationship, Drug</term><term>Drug Therapy, Combination</term><term>Extrapyramidal symptoms</term><term>Female</term><term>Human</term><term>Humans</term><term>Levodopa</term><term>Male</term><term>Middle Aged</term><term>Neuroleptic</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Pilot Projects</term><term>Psychiatric Status Rating Scales</term><term>Psychoses, Substance-Induced (drug therapy)</term><term>Psychosis</term><term>Psychotropic</term><term>Risperidone</term><term>Risperidone (therapeutic use)</term><term>Serotonin antagonist</term><term>Serotonine receptor</term><term>Short term</term><term>Toxicity</term><term>Treatment</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term><term>Dopamine Antagonists</term><term>Risperidone</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Belgium</term><term>Canada</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term><term>Psychoses, Substance-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Dose-Response Relationship, Drug</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pilot Projects</term><term>Psychiatric Status Rating Scales</term><term>Treatment Outcome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Antagoniste dopamine</term><term>Antagoniste sérotonine</term><term>Antiparkinsonien</term><term>Chimiothérapie</term><term>Court terme</term><term>Homme</term><term>Lévodopa</term><term>Neuroleptique</term><term>Parkinson maladie</term><term>Psychose</term><term>Psychotrope</term><term>Rispéridone</term><term>Récepteur dopaminergique</term><term>Récepteur sérotoninergique</term><term>Toxicité</term><term>Traitement</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Belgique</term><term>Canada</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">PURPOSE: To evaluate the safety and efficacy of risperidone in patients with Parkinson's disease (PD) who are experiencing significant dopamine‐induced psychosis. PATIENTS AND METHODS: Seventeen patients (median age, 72 yrs) participated in this 12‐week, open pilot study receiving 0.5 to 3 mg oral risperidone per day. Maintenance antiparkinsonian medication was continued throughout, although psychotropic medication was discontinued. EFFICACY RESULTS: Risperidone produced a substantial improvement in psychotic symptoms, shown on the mean total positive subscale score on the Positive and Negative Syndrome Scale (PANSS) by a 30% improvement (−3.1 decrease) after 1 week and a 66% improvement (−6.8 decrease) at end point. This improvement was most evident in the items delusions, hallucinatory behavior, and suspiciousness/persecution. Risperidone also achieved significant improvement from baseline in Clinical Global Impression (CGI)‐severity and CGI‐improvement (p <0.001, Page test). Risperidone treatment did not adversely affect symptoms specific to Parkinson's disease, as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS). SAFETY RESULTS: Sixteen patients reported at least one adverse event, but only two patients withdrew as a result of adverse events. No significant changes or clinically relevant abnormalities were observed in laboratory parameters or vital signs. CONCLUSION: Short‐term use of risperidone (mean dosage, 1.1 mg per day) improves the psychopathology of patients with PD who have dopamine‐induced psychosis without adversely affecting the symptoms of PD. Higher doses and long‐term use were not addressed in this study and may be precluded by extrapyramidal side effects.</div></front></TEI><affiliations><list><country><li>Belgique</li><li>Canada</li></country><region><li>Province d'Anvers</li></region><settlement><li>Anvers</li></settlement><orgName><li>Université d'Anvers</li></orgName></list><tree><country name="Canada"><noRegion><name sortKey="Mohr, Erich" sort="Mohr, Erich" uniqKey="Mohr E" first="Erich" last="Mohr">Erich Mohr</name></noRegion><name sortKey="Hildebrand, Kathleen" sort="Hildebrand, Kathleen" uniqKey="Hildebrand K" first="Kathleen" last="Hildebrand">Kathleen Hildebrand</name><name sortKey="Mendis, Tilak" sort="Mendis, Tilak" uniqKey="Mendis T" first="Tilak" last="Mendis">Tilak Mendis</name></country><country name="Belgique"><region name="Province d'Anvers"><name sortKey="De Deyn, Peter Paul" sort="De Deyn, Peter Paul" uniqKey="De Deyn P" first="Peter Paul" last="De Deyn">Peter Paul De Deyn</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004969 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004969 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:8B1FBAD976A77EB092B13F06364277175FC64B7A
|texte= Risperidone in the treatment of dopamine‐induced psychosis in Parkinson's disease: An open pilot trial
}}
| This area was generated with Dilib version V0.6.23. |  |